Hale BORAZAN, Mine ÖZDEN, Tuba B. ERDEM, Alper YOSUNKAYA, Selmin ÖKESLİ

Sevofluran ve malign hipertermi: Geciken dantrolen tedavisi

Malign hipertermi (MH), çoğunlukla anestezi ile ilişkili olan, volatil anestezikler ve depolarizan kas gevşeticilerle tetiklenen, hipertermi, taşikardi, asidoz ve kas rijiditesi ile karakterize bir durumdur. Bu olguda, serebral palsi nedeniyle alt extremite spastisitesinin tedavisi için ameliyat edilecek 5 yaşındaki kız çocuğu sunulmaktadır. Sevoşuran ile yapılan maske indüksiyonundan 60 dakika sonra MH’den şüphelendiren semptomlar görülmüş ve hasta ancak 36 saat sonra temin edilebilen dantrolen ile tedavi edilerek sekelsiz iyileşmiştir. Malign hiperterminin klinik belirtilerinden şüphelenilmesinin hızlı tanı ve tedaviye olanak sağlayacağı kanaatindeyiz. özellikle ülkemizdeki anestezi kliniklerinde, dantrolenin ulaşılabilir olmasının önemi belirtilmek istenmiştir.

Sevoflurane and malignant hyperthermia: Delayed dantrolene treatment

Malignant hyperthermia (MH) is almost associated with anesthesia, triggered by volatile anesthetics, depolarizing neuromuscular blockers and is characterized by hyperthermia, tachycardia, acidosis and muscle rigidity. In this case report, we present a five-year-old girl who was operated for treatment approaches for lower extremity spasticity in cerebral palsy. After sixty minutes of anesthesia induction with only sevoflurane via facemask, symptoms of suspicious malignant hyperthermia was seen in the patient and she was treated with dantrolene that was found thirty-six hours later the acute crisis and she recovered without sequel. We think that suspecting clinical signs of malignant hyperthermia would allow fast diagnosis and treatment. Here, we want to mention the importance of dantrolene availability in the anesthesia clinics especially in our country.

PDF

___

1. Jurkat-Rott K, McCarthy T, Lehmann-Horn F. Genetics and pathogenesis of malignant hyperthermia. Muscle and Nerve 2000; 23: 4-17.
2. Claxton BA, Cross MH, Hopkins PM. No response to trigger agents in a malignant hyperthermia-susceptible patient. Br J Anaesth 2002; 88: 870-3.
3. Gerçek A, Tural S, Konya D, Özek MM. Malign Hipertermi Öyküsü Olan Çocuk Olguda Genel Anestezi Yönetimi. Türk Anest Rean Der Dergisi 2008; 36(4): 250-52.
4. Bonciu M, De La Chapelle A, Delpech H, et al. Minor increase of endtidal CO2 during sevoşurane-induced malignant hyperthermia. Paediatr Anaesth 2007; 17: 180-2.
5. Hopkins PM. Malignant Hyperthermia: advances in clinical management and diagnosis. Br J Anaesth 2000; 85: 118-28.
6. Larach MG, Locallio AR, Allen GC, et al. A Clinical Grading Scale to Predict Malignant Hyperthermia Susceptibility. Anesthesiology 1994; 80: 771-9.
7. Antognini JF. Creatine kinase alterations after acute malignant hyperthermia episodes and common surgical procedures. Anesth Analg 1995; 81: 1039-42.
8. Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F. Dantrolen-a review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004; 59: 364-73.
9. Podranski T, Bouillon T, Schumacher PM, Taguchi A, Sessler DI, Kurz A. Compartmental Pharmacokinetics of Dantrolen in Adults: Do Malignant Hyperthermia Association Dosing Guidelines Work?. Anesth Analg 2005; 101: 1695-9.
10. Ducart A, Adnet P, Renoud B, Riou B, Krivosic-Horber R. Malignant Hyperthermia During Sevoşurane Administration. Anesth Analg 1995; 80: 609-11.
11. Monnier N, Proccacio V, Stieglitz P, Lunardi J. Malignant Hyperthermia Susceptibility is Associated with a Mutation of the alpha 1-Subunit of the Human Dihydropyridine-Sensitive L- type Voltage-Dependent Calcium-Chanel Receptor In Skeletal Muscle. Am J Hum Genet 1997; 60(6): 1316-25.
12- Marchant CL, Ellis FR, Halsall PJ, Hopkins PM, Robinson RL. Mutation analysis of two patients with hypokalemic periodic paralysis and suscepted malignant hyperthermia. Muscle Nerve 2004; 30(1): 114-17.
13. Larach MG, Brandom BW, Allen GC, Gronert GA, Lehman EB. Cardiac arrests and deaths associated with malignant hyperthermia in North America from 1987 to 2006: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States. Anesthesiology 2008; 108: 603-611.
14. Ording H, Brancadoro V, Cozzolino S, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol European MH group: Results of testing patients surviving fulminant MH and unrelated low-risk subjects. Acta Anaesthesiol Scand. 1997; 41: 955-66.